[1] Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, Holtzman DM, Jagust W, Jessen F, Karlawish J, Liu E, Molinuevo JL, Montine T, Phelps C, Rankin KP, Rowe CC, Scheltens P, Siemers E, Snyder HM, Sperling R (2018) NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement14, 535-562.
[2] Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, Fox NC, Marcus DS, Cairns NJ, Xie X, Blazey TM, Holtzman DM, Santacruz A, Buckles V, Oliver A, Moulder K, Aisen PS, Ghetti B, Klunk WE, McDade E, Martins RN, Masters CL, Mayeux R, Ringman JM, Rossor MN, Schofield PR, Sperling RA, Salloway S, Morris JC (2012) Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med367, 795-804.
[3] Victor L Villemagne SB, Pierrick Bourgeat, Belinda Brown, Kathryn A Ellis, Olivier Salvado, Cassandra Szoeke, S Lance Macaulay, Ralph Martins, Paul Maruff, David Ames, Christopher C Rowe, Colin L Masters, (2013) Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. Lancet Neurol12, 11.
[4] Lu Y, Li Z, Zhang X, Ming B, Jia J, Wang R, Ma D (2010) Retinal nerve fiber layer structure abnormalities in early Alzheimer's disease: evidence in optical coherence tomography. Neurosci Lett480, 69-72.
[5] Berisha F, Feke GT, Trempe CL, McMeel JW, Schepens CL (2007) Retinal abnormalities in early Alzheimer's disease. Invest Ophthalmol Vis Sci48, 2285-2289.
[6] Mejia-Vergara AJ, Restrepo-Jimenez P, Pelak VS (2020) Optical Coherence Tomography in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. Front Neurol11, 578698.
[7] Gupta VB, Chitranshi N, den Haan J, Mirzaei M, You Y, Lim JK, Basavarajappa D, Godinez A, Di Angelantonio S, Sachdev P, Salekdeh GH, Bouwman F, Graham S, Gupta V (2020) Retinal changes in Alzheimer's disease- integrated prospects of imaging, functional and molecular advances. Prog Retin Eye Res, 100899.
[8] Uchida A, Pillai JA, Bermel R, Bonner-Jackson A, Rae-Grant A, Fernandez H, Bena J, Jones SE, Leverenz JB, Srivastava SK, Ehlers JP (2018) Outer Retinal Assessment Using Spectral-Domain Optical Coherence Tomography in Patients With Alzheimer's and Parkinson's Disease. Invest Ophthalmol Vis Sci59, 2768-2777.
[9] Asanad S, Ross-Cisneros FN, Nassisi M, Barron E, Karanjia R, Sadun AA (2019) The Retina in Alzheimer's Disease: Histomorphometric Analysis of an Ophthalmologic Biomarker. Invest Ophthalmol Vis Sci60, 1491-1500.
[10] Alber J, Goldfarb D, Thompson LI, Arthur E, Hernandez K, Cheng D, DeBuc DC, Cordeiro F, Provetti-Cunha L, den Haan J, Van Stavern GP, Salloway SP, Sinoff S, Snyder PJ (2020) Developing retinal biomarkers for the earliest stages of Alzheimer's disease: What we know, what we don't, and how to move forward. Alzheimers Dement16, 229-243.
[11] Cheng DL, Thompson L, Snyder PJ (2019) A Potential Association Between Retinal Changes, Subjective Memory Impairment, and Anxiety in Older Adults at Risk for Alzheimer's Disease: A 27-Month Pilot Study. Front Aging Neurosci11, 288.
[12] Ito Y, Sasaki M, Takahashi H, Nozaki S, Matsuguma S, Motomura K, Ui R, Shikimoto R, Kawasaki R, Yuki K, Sawada N, Mimura M, Tsubota K, Tsugane S (2020) Quantitative Assessment of the Retina Using OCT and Associations with Cognitive Function. Ophthalmology127, 107-118.
[13] Kim JI, Kang BH (2019) Decreased retinal thickness in patients with Alzheimer's disease is correlated with disease severity. PLoS One14, e0224180.
[14] Choi SH, Park SJ, Kim NR (2016) Macular Ganglion Cell -Inner Plexiform Layer Thickness Is Associated with Clinical Progression in Mild Cognitive Impairment and Alzheimers Disease. PLoS One11, e0162202.
[15] McCoskey M, Addis V, Goodyear K, Sankar PS, Ying GS, Yu Y, Salowe R, Cui QN, Miller-Ellis E, Maguire M, JM OAB (2018) Association between Primary Open-Angle Glaucoma and Cognitive Impairment as Measured by the Montreal Cognitive Assessment. Neurodegener Dis18, 315-322.
[16] Sharafi SM, Sylvestre JP, Chevrefils C, Soucy JP, Beaulieu S, Pascoal TA, Arbour JD, Rhéaume MA, Robillard A, Chayer C, Rosa-Neto P, Mathotaarachchi SS, Nasreddine ZS, Gauthier S, Lesage F (2019) Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images. Alzheimers Dement (N Y)5, 610-617.
[17] Yan Y, Wu X, Wang X, Geng Z, Wang L, Xiao G, Wu Y, Zhou S, Wei L, Tian Y, Wang K (2021) The Retinal Vessel Density Can Reflect Cognitive Function in Patients with Alzheimer's Disease: Evidence from Optical Coherence Tomography Angiography. J Alzheimers Dis.
[18] Yoon SP, Grewal DS, Thompson AC, Polascik BW, Dunn C, Burke JR, Fekrat S (2019) Retinal Microvascular and Neurodegenerative Changes in Alzheimer's Disease and Mild Cognitive Impairment Compared with Control Participants. Ophthalmol Retina3, 489-499.
[19] den Haan J, van de Kreeke JA, van Berckel BN, Barkhof F, Teunissen CE, Scheltens P, Verbraak FD, Bouwman FH (2019) Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease? Alzheimers Dement (Amst)11, 383-391.
[20] Battle DE (2013) Diagnostic and Statistical Manual of Mental Disorders (DSM). Codas25, 191-192.
[21] Manly GMMDSKHCBTHCRJJCHKWEKWJKJJ (2011) The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement.
[22] Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, Chai X, Proctor NK, Eichenlaub U, Zetterberg H, Blennow K, Reiman EM (2020) Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med26, 379-386.
[23] Cullen NC, Leuzy A, Palmqvist S, Janelidze S, Stomrud E, Pesini P, Sarasa L, Allué JA, Proctor NK, Zetterberg H, Dage JL, Blennow K, Mattsson-Carlgren N, Hansson O (2021) Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations. Nature Aging1, 114-123.
[24] Frizziero L, Parrozzani R, Londei D, Pilotto E, Midena E (2020) Quantification of vascular and neuronal changes in the peripapillary retinal area secondary to diabetic retinopathy. Br J Ophthalmol.
[25] Santos CY, Johnson LN, Sinoff SE, Festa EK, Heindel WC, Snyder PJ (2018) Change in retinal structural anatomy during the preclinical stage of Alzheimer's disease. Alzheimers Dement (Amst)10, 196-209.
[26] O'Bryhim BE, Apte RS, Kung N, Coble D, Van Stavern GP (2018) Association of Preclinical Alzheimer Disease With Optical Coherence Tomographic Angiography Findings. JAMA Ophthalmol136, 1242-1248.
[27] Jiang H, Wei Y, Shi Y, Wright CB, Sun X, Gregori G, Zheng F, Vanner EA, Lam BL, Rundek T, Wang J (2018) Altered Macular Microvasculature in Mild Cognitive Impairment and Alzheimer Disease. J Neuroophthalmol38, 292-298.
[28] Salobrar-Garcia E, Méndez-Hernández C, Hoz R (2020) Ocular Vascular Changes in Mild Alzheimer's Disease Patients: Foveal Avascular Zone, Choroidal Thickness, and ONH Hemoglobin Analysis. J Pers Med10.
[29] Masuzzo A, Dinet V, Cavanagh C, Mascarelli F, Krantic S (2016) Amyloidosis in Retinal Neurodegenerative Diseases. Front Neurol7, 127.
[30] Vandenabeele M, Veys L, Lemmens S, Hadoux X, Gelders G, Masin L, Serneels L, Theunis J, Saito T, Saido TC, Jayapala M, De Boever P, De Strooper B, Stalmans I, van Wijngaarden P, Moons L, De Groef L (2021) The App(NL-G-F) mouse retina is a site for preclinical Alzheimer's disease diagnosis and research. Acta Neuropathol Commun9, 6.
[31] Chua J, Hu Q, Ke M, Tan B, Hong J, Yao X, Hilal S, Venketasubramanian N, Garhöfer G, Cheung CY, Wong TY, Chen CL, Schmetterer L (2020) Retinal microvasculature dysfunction is associated with Alzheimer's disease and mild cognitive impairment. Alzheimer's Research & Therapy12, 161.
[32] Bulut M, Kurtuluş F, Gözkaya O, Erol MK, Cengiz A, Akıdan M, Yaman A (2018) Evaluation of optical coherence tomography angiographic findings in Alzheimer's type dementia. Br J Ophthalmol102, 233-237.
[33] Grimaldi A, Brighi C, Peruzzi G (2018) Inflammation, neurodegeneration and protein aggregation in the retina as ocular biomarkers for Alzheimer's disease in the 3xTg-AD mouse model. Cell Death Dis9, 685.
[34] Szegedi S, Dal-Bianco P, Stögmann E, Traub-Weidinger T, Rainer M, Masching A, Schmidl D (2020) Anatomical and functional changes in the retina in patients with Alzheimer's disease and mild cognitive impairment. Acta Ophthalmol.98, e914-e921.
[35] Mejia-Vergara AJ, Karanjia R, Sadun AA (2020) OCT parameters of the optic nerve head and the retina as surrogate markers of brain volume in a normal population, a pilot study. J Neurol Sci420, 117213.
[36] van de Kreeke JA, Nguyen HT, Konijnenberg E, Tomassen J, den Braber A, Ten Kate M, Yaqub M, van Berckel B, Lammertsma AA, Boomsma DI, Tan HS, Visser PJ, Verbraak FD (2020) Longitudinal retinal layer changes in preclinical Alzheimer's disease. Acta Ophthalmol.
[37] Song W, Shao W, Yi W, Liu R, Desai M, Ness S, Yi J (2020) Visible light optical coherence tomography angiography (vis-OCTA) facilitates local microvascular oximetry in the human retina. Biomed Opt Express11, 4037-4051.